About cardiovascular disease

Committed to helping you identify cardiovascular risk

Cardiovascular disease (CVD) continues to be the leading cause of death in the US¹ Guidelines are evolving to implement new kinds of cardiovascular testing that may help save millions of lives. Quest Diagnostics is at the forefront, dedicated to incorporating advanced testing methods that provide accurate results.

CVD statistics at a glance1

  • 1 in every 3 deaths in the US is related to CVD
  • About 2,300 Americans die of CVD each day—one every 38 seconds
  • 720,000 Americans per year will have a heart attack for the first time
  • Nearly half of all heart attack patients are found to have no prior risk that would indicate they are heading toward an attack
  • Many of the risk factors contributing to CVD are modifiable—such as smoking, physical inactivity, and nutrition

Injury and inflammation: the key to CVD risk assessment

The beginnings of CVD are rooted in injury to the arterial wall. Risk factors like smoking, hypertension, and diabetes injure the arterial wall, making it more susceptible to penetration and accumulation of excess lipids.

The inflammatory response to injury contributes to the progression of plaque development and is a key factor in the formation of vulnerable plaque and plaque rupture, which may cause a heart attack or stroke.

Evolving guidelines continue to focus on traditional factors to manage cardiovascular risk

Residual cardiovascular risk is still significant despite managing
traditional risk factors

Standard lipid screening—assessing LDL levels—plays an important role in cardiovascular risk assessment, but it may not always be predictive of adverse events. Residual cardiovascular risk can still be significant despite managing traditional risk factors.2

The AHA Get-With-The-Guidelines® initiative analysis revealed that a substantial proportion of CHD event patients were well within guideline-recommended targets for lipid panel values.3

 

Identifying residual risk: advanced lipid testing

Going beyond standard lipid panels to assess lipoprotein, apolipoprotein, inflammatory, metabolic, and genetic risk factors may provide deeper insights into the residual risk of your patients.

Advanced biomarkers have been shown to help identify residual risk and have been adopted by several guidelines and societies.4,5 With deeper insights, you can take further action to help reduce your patients’ risk for adverse cardiovascular events. Learn more.

Uncovering hidden risk: advanced inflammatory marker testing

Through our Cleveland HeartLab Cardiometabolic Center of Excellence, Quest offers expanded, unique inflammation testing that may provide additional and complementary insight into cardiovascular risk beyond lipid testing alone.

Cardio IQ® inflammation testing consists of simple blood and urine biomarkers that may help identify inflammatory risk across a risk spectrum. This additional information allows for targeted treatment to reduce risk over a patient’s lifetime. Learn more.

When CVD risk is hereditary: cardiogenetic testing

In many patients, the risk of CVD may be attributed to nonlipid factors, including genetic polymorphisms and mutations. Quest offers cardiogenetic testing to aid in early diagnosis and earlier treatment for affected patients as well as family members. Learn more.

Know the early warning signs: metabolic testing

Patients who have metabolic syndrome are at higher risk of multiple chronic conditions, including diabetes, coronary heart disease, and cancer, as well as stroke. Some factors contributing to metabolic syndrome are genetic, while others can be modified with lifestyle changes.

The American Heart Association gauges the cardiovascular health of the US by tracking 7 key factors and behaviors that increase the risk for heart disease and stroke. Diabetes is one of these key factors.1 Quest offers a full range of Cardio IQ® testing options to evaluate patients’ metabolic and cardiovascular risk so you can take action to prevent or delay onset of chronic conditions, and to prevent adverse events such as stroke. Learn more.

Focus on prevention: heart failure testing

The recently updated ACCF/AHA guidelines for the management of heart failure recommend BNP or NT-proBNP biomarker testing followed by early intervention as an aid for prevention. Quest offers advanced biomarker testing to help prevent heart failure in your at-risk patients. Learn more.

 

References

1. Benjamin EJ, Virani SS, Callaway CW, et al. On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492.

2. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997;95(1):69-75.

3. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157:111-117.e2.

4. Third Report of the National Cholesterol Program (NCEP) Expert Panel. 2002; September; Section IV-8; tables IV2-2, IV2-3:108-110.

5. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101(12A):51F-57F.